A Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-6325 in Hepatitis C Infected Male and Female Patients.
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2014
At a glance
- Drugs MK 6325 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 06 Feb 2013 Actual initiation date changed from Apr 2011 to May 2011 as reported by ClinicalTrials.gov.
- 01 May 2012 Actual end date (1 Apr 2012) added as reported by ClinicalTrials.gov.
- 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.